Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

In The News

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Jun 8, 2014

New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patients

Dec 26, 2013

Oral RA Drug Shows Promise in Early Trial

Dec 23, 2013

Can-Fite BioPharma (CANF) Could Attract Radars on Top-Line Results, CombiMatrix (CBMX) on Contract w

Dec 23, 2013

Can-Fite jumps on positive rheumatoid arthritis treatment results

Dec 23, 2013

Can-Fite's CF101 meets in Phase IIb RA trial

Dec 23, 2013

Can-Fite’s CF101 delivers a can-do performance in RA

rss_feed RSS
  • arrow_back
  • 1
  • 2
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2023 Can-Fite All Rights Reserved

BrandWiz - Branding